Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

Athimalaipet V Ramanan,Neena Modi,Saskia N de Wildt,c4c Learning from COVID-19 Group,Beate Aurich,Sophia Bakhtadze,Francisco J Bautista Sirvent,Fernando Cabañas,Lisa Campbell,Michaela Casanova,Philippa Charlton,Wallace Crandall,Irmgard Eichler,Laura Fregonese,Daniel B Hawcutt,Pablo Iveli,Thomas Jaki,Bosanka Jocic-Jakubi,Mats Johnson,Florentina Kaguelidou,Bülent Karadag,Lauren E Kelly,Ming Lim,Carmen Moreno,Eva Neumann,Cécile Ollivier,Mehdi Oualha,Genny Raffaeli,Maria A Ribeiro,Emmanuel Roilides,Teresa de Rojas,Alba Rubio San Simón,Nicolino Ruperto,Maurizio Scarpa,Matthias Schwab,Angeliki Siapkara,Yogen Singh,Anne Smits,Pasquale Striano,Silvana A M Urru,Marina Vivarelli,Saskia de Wildt,Zorica Zivkoviz

DOI: https://doi.org/10.1038/s41390-021-01587-3

Abstract:Background: The COVID-19 pandemic has had a devastating impact on multiple aspects of healthcare, but has also triggered new ways of working, stimulated novel approaches in clinical research and reinforced the value of previous innovations. Conect4children (c4c, www.conect4children.org ) is a large collaborative European network to facilitate the development of new medicines for paediatric populations, and is made up of 35 academic and 10 industry partners from 20 European countries, more than 50 third parties, and around 500 affiliated partners. Methods: We summarise aspects of clinical research in paediatrics stimulated and reinforced by COVID-19 that the Conect4children group recommends regulators, sponsors, and investigators retain for the future, to enhance the efficiency, reduce the cost and burden of medicines and non-interventional studies, and deliver research-equity. Findings: We summarise aspects of clinical research in paediatrics stimulated and reinforced by COVID-19 that the Conect4children group recommends regulators, sponsors, and investigators retain for the future, to enhance the efficiency, reduce the cost and burden of medicines and non-interventional studies, and deliver research-equityWe provide examples of research innovation, and follow this with recommendations to improve the efficiency of future trials, drawing on industry perspectives, regulatory considerations, infrastructure requirements and parent-patient-public involvement. We end with a comment on progress made towards greater international harmonisation of paediatric research and how lessons learned from COVID-19 studies might assist in further improvements in this important area.